Transdermal Testing
Transdermal Testing - Related Videos
08:19
Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing
0 Views •
Cited by 34 •
2012
This article details the construction of a multiplexed microneedle-based sensor. The device is being developed for in situ sampling and electrochemical analysis of multiple analytes in a rapid and selective manner. We envision clinical medicine and biomedical research uses for these microneedle-based sensors.
01:18
Transdermal Drug Delivery Systems
0 Views •
2026
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
07:25
Transdermal Measurement of Glomerular Filtration Rate in Mice
0 Views •
Cited by 101 •
2018
Here we describe a protocol to measure glomerular filtration rate (GFR) in conscious, freely moving mice using a transdermal GFR monitor.
07:41
Transdermal Measurement of Glomerular Filtration Rate in Mechanically Ventilated Piglets
0 Views •
Cited by 8 •
2022
Glomerular filtration rate (GFR) is the ideal marker for assessing kidney function. However, the standard measurement method using inulin injection with serial blood and urine analysis is impractical. This article delineates a practical method to measure GFR transdermally in piglets.
07:47
Anxiety Testing
0 Views •
2023
Anxiety is a commonly observed behavioral disorder that stems from fear. It is described as increased restlessness, or unpleasant feelings of fear over anticipated events. Experimenters often use rodent models to better understand anxiety disorders in humans. They use different paradigms, like exposing rodents to bright spaces or loud sounds, which are known to induce fear. These tests combined with other interventions such as surgery or drug-administration may assist researchers in pinpointing...
FAQs
The stratum corneum acts as the principal barrier that a substance must cross before reaching deeper skin layers and potentially entering circulation. Its barrier role makes the extent and rate of movement central measurements in Transdermal Testing. By examining permeation under controlled exposure conditions, investigators can determine whether a formulation supports consistent passage rather than merely releasing its contents.
Permeation, absorption, and release describe different parts of performance, so analytical assays quantify them over time. Release indicates how the formulation makes the substance available, permeation tracks movement through the skin barrier, and absorption addresses uptake. Reviewing these time-dependent measurements helps reveal whether delivery is sustained and whether the dose becomes available in a reliable pattern.
Transdermal Testing can expose differences between a patch, gel, or other formulation that may not be apparent from formulation type alone. Controlled comparisons help identify factors affecting performance, then guide dose-delivery optimization. The practical goal is not simply greater passage through skin, but a reliable delivery profile suitable for the intended clinical development decision.
A typical assessment establishes controlled exposure conditions, applies the formulation being evaluated, and uses analytical assays to quantify movement and release over time. The resulting measurements are interpreted together rather than as a single endpoint, because permeation, absorption, and release address different stages of delivery. This workflow helps characterize how performance changes during the test.
These assessments are used before or alongside human studies to compare candidate formulations, optimize dose delivery, and examine performance relevant to safety and efficacy decisions. They can provide evidence about whether a patch, gel, or related approach delivers a reliable dose. Thus, testing connects formulation development with decisions about advancing a noninvasive treatment strategy.
A formulation that maintains delivery over time may support systemic treatment through a noninvasive route. Transdermal approaches are also relevant when developers want to avoid gastrointestinal degradation. Testing therefore evaluates more than skin passage: it helps determine whether the delivery pattern and route fit the intended therapeutic strategy and support subsequent safety or efficacy decisions.